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BACKGROUND: Human medulloblastomas exhibit diverse molecular pathology. Aberrant hedgehog signalling is found in 20–30% of
human medulloblastomas with largely unknown metabolic consequences.
METHODS: Transgenic mice over-expressing smoothened (SMO) receptor in granule cell precursors with high incidence of exophytic
medulloblastomas were sequentially followed up by magnetic resonance imaging (MRI) and characterised for metabolite phenotypes
by
1H MR spectroscopy (MRS) in vivo and ex vivo using high-resolution magic angle spinning (HR-MAS)
1H MRS.
RESULTS: Medulloblastomas in the SMO mice presented as T2 hyperintense tumours in MRI. These tumours showed low
concentrations of N-acetyl aspartate and high concentrations of choline-containing metabolites (CCMs), glycine, and taurine relative
to the cerebellar parenchyma in the wild-type (WT) C57BL/6 mice. In contrast,
1H MRS metabolite concentrations in normal
appearing cerebellum of the SMO mice were not different from those in the WT mice. Macromolecule and lipid
1H MRS signals in
SMO medulloblastomas were not different from those detected in the cerebellum of WT mice. The HR-MAS analysis of SMO
medulloblastomas confirmed the in vivo
1H MRS metabolite profiles, and additionally revealed that phosphocholine was strongly
elevated in medulloblastomas accounting for the high in vivo CCM.
CONCLUSIONS: These metabolite profiles closely mirror those reported from human medulloblastomas confirming that SMO mice
provide a realistic model for investigating metabolic aspects of this disease. Taurine, glycine, and CCM are potential metabolite
biomarkers for the SMO medulloblastomas. The MRS data from the medulloblastomas with defined molecular pathology is discussed
in the light of metabolite profiles reported from human tumours.
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Medulloblastoma is the most common malignant brain tumour of
childhood accounting for 25% of all paediatric brain tumours
(Taylor et al, 2005). It is an aggressive tumour, which commonly
invades surrounding structures with metastases being present in
over 90% of mortalities (Allen and Epstein, 1982). Medulloblas-
toma belongs to a group of tumours known as primitive
neuroectodermal tumours (PNETs), as they primarily consist of
cells that have an undifferentiated neuroepithelial, or stem-cell like
morphology (Hart and Earle, 1973). The tumour has the
characteristic of being highly cellular, with cells showing little
cytoplasm and nuclei with a high affinity for haematoxylin
(McLendon et al, 1999); so called ‘small round blue cells’.
Diagnosis is usually made from this appearance, and further
corroborated with immunostaining for neuronal markers, such as
synaptophysin.
Although histopathology is regarded as the ‘gold standard’
diagnostic investigation in clinical practise, other techniques
which measure the molecular profiles of tumour tissue may offer
complementary information on tissue function. Gene expression
profiling has been shown to be capable of detecting different
subtypes of medulloblastoma, leading to the discovery of
prognostic markers (Pomeroy et al, 2002). Of particular interest
are non-invasive methods, such as in-vivo
1H magnetic resonance
spectroscopy (MRS), which can measure the concentrations of
small molecules present in tissues. In vivo
1H MRS has identified
biomarkers which can be used to identify medulloblastoma
tumours which are likely to metastasise, (Peet et al, 2007a) and
these could potentially be used to identify the pathways which may
be suitable targets for drugs (Griffin and Shockcor, 2004). A
complementary technique to in vivo
1H MRS is high-resolution
magic angle spinning (HR-MAS), which allows a larger number of
metabolites to be resolved as well as the accurate detection of lower
concentration metabolites from biopsy tissue and cells grown in
culture (Peet et al, 2007b; Wilson et al, 2009a). This technique may
be used to validate findings from in vivo MRS, determine the
contributions of individual metabolites which can only be
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squantified in combination in vivo (Griffin et al, 2003; Davies et al,
2008) and additionally may reveal low concentration biomarkers
which are difficult to measure in vivo.
In addition to diagnosis and characterisation, in vivo
1H MRS is
well suited to assessing tumour response to treatment (Hakuma ¨ki
and Kauppinen, 2000; Nelson and Cha, 2003). It has been shown
that in favourable anti-cancer drug treatment and/or radiation
therapy of adult glioblastomas
1H MRS detectable metabolites
strongly decline (Nelson and Cha, 2003). Hakuma ¨ki et al (1999)
showed that
1H MRS can detect an increase in lipid signals as
tumours undergo gene therapy-induced cell death in a rat glioma
model. In addition high, lipids have been associated with high-
grade brain tumours in adults (Kuesel et al, 1994) and children
(Astrakas et al, 2004).
Of further importance to the understanding of medulloblastoma,
and in particular their response to treatment, is the development of
a realistic animal model. Preclinical testing of new agents is a pre-
requisite for human use and it is highly desirable for this to be
performed in an animal model. New molecularly targeted agents
are the focus of most anticancer drug development at present but
conventional imaging may provide a poor marker of response
(O’Connor et al, 2008). The development and validation of novel
imaging techniques in tandem with the new agent during the
preclinical phase would provide major benefits for the incorpora-
tion of this methodology in early phase clinical trials (O’Connor
et al, 2008). In addition, the study of paediatric brain tumour in
appropriate animal models should provide new therapeutic
insights into the human disease and might yield important
pathophysiological findings. In this study, a novel medulloblasto-
ma mouse model, the smoothened (SMO) mouse, developed by
Hatton et al (2008), is investigated using MR imaging (MRI) and
1H MRS methods, both in vivo and ex vivo, to characterise its
morphologic and molecular features. The SMO mouse model has
high levels of the activated form of SMO receptor in Sonic
hedgehog (Shh) signalling pathway, which results in a high rate of
medulloblastoma formation and early cerebellar hyperprolifera-
tion (Hatton et al, 2008). The Shh pathway is crucial for normal
development of the cerebellum. The mutations in the patched
(Ptch) gene in the Shh pathway contribute to SMO mice developing
subclinical medulloblastoma by two months of age. The close
adherence to human pathology, high incidence, a greater latency
period, and early onset of tumours thus make SMO mice an
efficient model for preclinical studies and for further investigating
the series of events leading to tumour formation and progression,
however, the metabolic profile of these tumours has not been
established.
In this work, we have used MRI and
1H MRS to determine the
metabolite profile in the SMO medulloblastomas in vivo and ex
vivo allowing a comparison with childhood medulloblastomas and
establishing a test bed for
1H MRS biomarkers from this malignant
brain tumour with defined molecular pathology.
1H MRS was used
to identify the presence of the tumours, to follow their progression
in contrast to MRI method, because of the weak contrast
enhancement in the tumour.
MATERIALS AND METHODS
The ND2:SmoA1 mouse line (the SMO mouse) was a generous gift
from Fred Hutchinson Cancer Research Center (Seattle, WA, USA)
and was generated as previously described (Hallahan et al, 2004;
Hatton et al, 2008). Adult homozygous SMO mice were maintained
under sterile conditions in accordance with the Institutional
Animal Care and Use Committee at the Dartmouth Medical School.
Wild-type (WT) male C57BL6 mice were purchased from Charles
River Laboratories. All mice were monitored on a regular basis for
signs of illness or tumour effects, such as symptoms of protruded
head and lethargy.
In vivo MRI and MRS were performed on the SMO and WT
mice. SMO mice (n¼19) ranging from 55 to 229 days and WT of
over 120 days of age were used for the study (weight ranging from
20 to 30g). All MR experiments were performed on a 7T/21cm
magnet (Magnex Scientific, Abingdon, UK) equipped with an
imaging gradient set (Resonance Research Inc, Billerica, MA,
USA), interfaced to a Varian INOVA console (Varian, Palo Alto,
CA, USA). A single tuned one turn surface coil with diameter of
15mm diameter was used in transmit/receive mode. The mice were
anaesthetised with isoflurane (1–1.5 volume % in 70:30 O2:air)
with a nosecone and animal torso was placed on a thermostated
water circulating heating element at 371C for the duration of MR
scans. In all MR experiments, a multislice multiecho sequence was
used to acquire T2-weighted images and to position the voxel for
1H MRS studies with following parameters: time to repetition (TR)
3s, echo train length 8, echo spacing 15ms, effective echo time
(TE) 60ms, number of phase encoding steps 128, FOV
32 28mm
2, sagittal orientation, slice thickness 0.75mm, number
of transients 4. The multi slice spin echo T1-weighted images
before and 15min after contrast agent injection (Magnevist, Bayer
Inc., Wayne, NY, USA; 0.2mmolkg
–1 i.p.) were acquired with
same field of view and thickness but with TR of 0.7s, TE of 9ms.
For single voxel
1H localised MRS shimming was performed
using FASTESTMAP (Gruetter, 1993; Gruetter and Tkac, 2000),
resulting in a 10–17Hz full width at half height of the water
resonance in an 8ml voxel (2 2 2mm
3). Voxels were centred to
the T2 hyperintense tumour in the SMO mice or in the cerebellum
of WT mice (and those SMO mice showing normal T2 MRI) to
minimise partial volume effects. Localisation by adiabatic selective
refocusing (Garwood and DelaBarre, 2001) technique was used for
single voxel with TR of 3s and TE of 26ms, with 256 signal
averages. The water signal was efficiently suppressed by variable
power RF pulses with optimised relaxation delays (Tkac et al,
1999). Unsuppressed water signal was acquired at the end of the
experiments for quantification of metabolites (eight averages). The
receiver gain and signal averages were taken into account for
quantification.
Magic angle spinning
Tumour and brain tissues were stored at  801C until
analysis, thawed on dry ice, and cut to approximately 20mg
specimens for
1H HR-MAS. The tissue was then placed into a 30ml
Kel-F rotor insert and weighed. 3ml 3-(trimethylsilyl) propionic-
2,2,3,3-d4 acid (sodium salt) was dissolved in D2O at a concentra-
tion of 5mM and added to the rotor insert. The remaining volume
of the rotor was filled with D2O to ensure consistent spinning for
each sample.
The
1H HR-MAS was performed on a Bruker 500MHz vertical-
bore spectrometer using a 4mm HRMAS
1H-
13C NMR probe with
a z-gradient (Bruker UK Limited, Coventry, UK) with an Advance
III console running TOPSPIN 2.1 software. The sample was spun at
5000Hz at a temperature of 271C determined by methanol
calibration. A 1D NOESY pre-saturation pulse sequence was used,
which consisted of a single 901 pulse preceded by NOESY water
pre-saturation. The 901 pulse was followed by the acquisition of
32K complex points acquired with a spectral width of 16p.p.m.
The sequence had a repetition time of 4s and 64 or 128 scans were
acquired depending on the sample size.
Histology
A subgroup of animals were killed at the end of scan and the brain
tissue was removed from skull and rinsed in cold phosphate-
buffered saline (PBS) and fixed in 4% paraformaldehyde in PBS
solution and kept for overnight. The fixated brains were
cryoprotected with 20% glycerol solution in 20mM PBS for 24h.
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sectioned.
Serial sagittal 10–15-mm cryostat sections, corresponding to MR
images, were mounted on glass slides and stained with hemato-
xylin and eosin (Fisher, Pittsburgh, PA, USA) using standard
methods. Stained sections were examined with a Nikon E800
microscope (Nikon, Melville, NY, USA). Histological pictures were
viewed using a colour camera and software (version 3.0, Diagnostic
Instruments, Sterling Heights, MI, USA).
Data analysis
Magnetic resonance imaging The Aedes routine (http://aedes.
uku.fi) under Matlab platform (Mathworks Inc, Bolder, CO, USA)
was used to determine length of cerebrum and cerebellum at
midline as well as size of 4th ventricle from multislice sagittal
T2 scans.
Spectroscopic analysis In vivo and HR-MAS
1H MR spectra were
automatically phased and referenced to the creatine peak at
3.03p.p.m. before being analysed using the TARQUIN algorithm
for in vivo MRS as described by workers Wilson et al (2010).
Simulated basis sets were generated assuming ideal pulses, and
metabolite parameters were taken from (Govindaraju et al, 2000).
For HR-MAS data metabolite chemical shifts were manually
optimised using wxNUTS (Acorn NMR Inc, CA, USA) to account
for the difference in temperature between in vivo and in vitro.
In vivo metabolite concentrations were determined from the
unsuppressed water experiment, assuming an MR visible water
molarity of 35880mM. Metabolite quantities are expressed as
ratios to creatine for the HR-MAS data as this metabolite was
found to have a stable concentration across samples.
Statistical analysis Metabolite quantities were imported into the
R statistics package (Team, 2009) and the Student’s t-test and one-
way analysis of variance methods were used to determine
differences between the WT and SMO mice.
RESULTS
The sagittal T2-weighted images from two SMO mice show mass
that covers a large volume of the cerebellum (Figure 1A) or
presents as a solitary tumour in the base of the cerebellum
(Figure 1B). The foliage pattern of cerebellum was absent in the
T2 hyperintense tumours. In the mouse in Figure 1A, a severe
hydrocephalus with gross brain deformity is evident. A total of 19
SMO mice were scanned with three types of cerebellar appearances
in T2-weigthed RARE MRI as follows: (a) no obvious abnormality
(n¼10), the age of these mice varied from 55 to 220 days; (b) focal
hyperintense tumour (n¼2, Figure 1B), these mice were 119 and
180 days old; and (c) widespread hyperintensity and large-sized
ceberellum (n¼7, Figure 1A), the age range of these mice was
from 69 to 229 days. A T1-weighted image obtained before
(Figure 1D) and after contrast agent injection (Figure 1E) show
signal enhancement in the periphery of the tumour (for a
T2-weighted MRI of this mouse, see Figure 1F) that was commonly
observed in the SMO medulloblastomas studied.
A typical macroscopic brain phenotype of SMO mice is
displayed (Figure 2A), where the cerebellum is grossly enlarged
approaching the size of the forebrain. This mouse showed
widespread T2 hyperintensity in the cerebellum with hydrocephalus.
A plot between cerebellum-to-forebrain length ratio and the
volume of fourth ventricle shows that in a large number of SMO
mice both the ratio and the fourth ventricle were higher than in
WT mice (Figure 3). Histological sections for focal (Figure 2B) and
uniform (Figure 2C and D) medulloblastomas are displayed. The
histological slices showed high cell density in the external granular
layer in the cerebellum. Small dark and dense cells that are stained
strongly with hematoxylin, with disappearance of foliage pattern
in MRI images are the microscopic hallmarks indicative of
medulloblastomas.
Typical
1H MR spectra from WT cerebellum (a), SMO mouse
cerebellum with (b) and without (c) T2 MRI hyperintense tumour
are shown (Figure 4). It is evident that the
1H MR spectrum of
a tumour in a SMO mouse has a very small resonance
associated with N-acetyle aspartate (NAA) and grossly elevated
Figure 1 T2 MR images from the SMO (A and B) and WT (C) mice. Arrows point to T2 hyperintensity in the cerebellum because of medulloblastoma
tumours. T1-weighted MR images from mouse in panel B before (D) and 15min after (E) i.p. injection of Magnevist. An arrow in (E) shows the signal
enhancement in the tumour periphery. A T2-weighted image from the mouse in (D and E) is shown in (F). Details for MRI given under Materials and
Methods section.
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normal appearing creatine resonance. Interestingly, the chemical
shift region at 1.3 and 0.9p.p.m. in the spectrum from the SMO
medulloblastoma shows only weak signal from lipids, lactate and
macromolecules. Quantitative metabolite data are shown in
Table 1. It is evident that NAA in medulloblastomas (pooled
MRS data from all eight SMO mice with pathological cerebellum in
T2 MRI) is severely reduced, whereas taurine, glycine, and CCM
are highly elevated. Lactate, macromolecules and lipids in the
chemical shift region between 0.9 and 1.4p.p.m. are similar in
medulloblastomas and WT mice. In the cerebella of the SMO mice
without MRI abnormality, all metabolites, macromolecules and
lipids were within the range determined in the cerebella of the WT
mice (Table 1).
Example
1H HR-MAS spectra from SMO mouse with T2
MRI-detected tumour (a) and WT mouse (b) are shown (Figure 5).
The increased resolution of HR-MAS confirms the assignments
and trends detected in vivo and provides additional metabolic
information. The three choline-containing compounds are
clearly separable and it is clear that the increase in CCM seen in
the SMO medulloblastomas in vivo are as a result of an increase
in phosphocholine (PC) with glycerophoshocholine remaining
stable, a significant reduction in choline is also shown.
As shown in Table 1, total creatine concentration in vivo was not
different between the animals and therefore, we used creatine
as a reference for HR-MAS. In addition to changes in CCM,
increases in taurine, glycine, and NAA accompanied with
decreases in myo-inositol and g-amino butyrate (GABA) are
apparent from the spectra. Quantitative data for metabolites are
shown in Table 2.
DISCUSSION
Mouse models that mimic molecular pathology of human
cancers provide a tremendous benefit towards molecular
understanding of tumour biology. There are more than 15
genetically engineered mouse models for medulloblastoma
Figure 2 Macroscopic CNS phenotype of a SMO mouse (A), and hematoxylin and eosin sections from a widespread (B) and focal (C)
medulloblastomas with a  3 enlargement on right of them.
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Figure 3 A plot between the cerebellum-to-forebrain length ratio and
the volume of the fourth ventricle from WT and SMO mice with and
without T2 MRI abnormality.
Magnetic resonance spectroscopy of a mouse medulloblastoma
SK Hekmatyar et al
1300
British Journal of Cancer (2010) 103(8), 1297–1304 & 2010 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
savailable for preclinical studies (Goodrich et al, 1997; Fomchenko
and Holland, 2006; Hatton et al, 2006). Very few of these
mouse models generate spontaneous tumours, however, and
tumours may differ histologically and genetically from human
medulloblastomas. To generate a closely human medulloblastoma
resembling model Hatton et al (2008) have cloned the SMO
receptor and developed the ND2:SmoA1 transgenic mouse with
spontaneous medulloblastomas sharing several characteristics of
human medulloblastoma. These include histopathology of
exophytic medulloblastoma, leptomeningeal spread and clinical
presentation characterised by ataxia and hydrocephalus.
The adherence to human pathology, high incidence, a shorter
latency period, and early onset of tumours thus make the SMO
mice an excellent animal model for preclinical studies of
medulloblastomas.
Our data show that the SMO medulloblastomas resemble
closely human medulloblastomas in terms of T2 hyper-
intense appearance. The
1H MRS evaluation of genetically
engineered medulloblastoma model has not been reported
before. The evaluation of brain tumours by means of
1H MRS
has mainly relied upon metabolite ratios such as NAA/CCM,
NAA/creatine, or CCM/creatine. There are several MRS
studies involving the human medulloblastoma in children
reported elsewhere (Girard et al, 1998; Tzika et al, 2002;
Astrakas et al, 2004; Panigrahy et al, 2006; Davies et al, 2008).
Human studies have shown that the primary tumours of
metastatic medulloblastoma have increased levels of CCM
and low level of lipids (Wilson et al, 2009b). Wilson et al
(2009b) have reported that there was a good correlation
between metabolite quantities detected by ex vivo
1H HR-MAS
and in vivo
1H MRS data. We found that the medulloblastomas in
the SMO mice have decreased NAA and elevated CCMs, taurine,
and glycine. This resembles closely the metabolic pattern observed
in human low grade medulloblastomas with heterogeneous
molecular pathology (Peet et al, 2004). Low levels of NAA and
GABA (by HR-MAS ex vivo) in the SMO medulloblastomas
probably reflect loss of the neuronal phenotype by the transformed
granule cells.
Given that the majority of the SMO mice with T2 MRI
hyperintense tumours were in their adulthood, it is pertinent to
compare metabolite profiles detected in mice with those reported
from human adult medulloblastomas and/or PNETs. In vitro
1H MRS analysis has revealed high concentrations of total choline-
containing phospholipids in extracts from adult medulloblastomas
(Srivastava et al, 2010). Using in vivo
1H MRS, Majos et al (2002)
found that adult medulloblastomas have low NAA and creatine,
but elevated CCM and lactate/lipids. More recently a short TE
1H
MRS study (Moreno-Torres et al, 2004) showed high taurine
concentration in adult medulloblastomas. In the light of the
present knowledge, the SMO and adult medulloblastomas share
metabolite similarities such as high CCM and taurine, and low
NAA, but levels of creatine and lactate/lipids in these tumours may
be at variance. Clearly, more data are required from adult
medulloblastomas to allow for full comparison of
1H MRS
metabolite profiles with childhood tumours or with any preclinical
medulloblastoma model.
A highly elevated taurine was observed in posterior
fossa tumour in children (Schneider et al, 2007). In agreement
with previous reports (Schneider et al, 2007; Davies et al, 2008), we
have found a consistent and elevated resonance from the taurine
peak at 3.3p.p.m. which is probably indicating the aggressive
behaviour of medulloblastoma. Taurine is an aminosulfonic
acid, and is abundant in the developing cerebellum and outermost
layer of the cerebellum. It has been postulated that increased
taurine is associated with an increased cellular proliferation and
aggressive nature of tumour (Wilson et al, 2009b). These findings
underline the importance of taurine and other metabolites
together, as imaging biomarkers of higher malignancy in
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Figure 4
1H MRS in vivo spectra from and (A) WT mouse cerebellum,
(B) SMO mouse cerebellum without T2 hyperintense lesion and (C) SMO
mouse cerebellum with a T2 hyperintense tumour. Peak assignments are
as follows: (1) lipids and macromolecules at 0.9p.p.m., (2) lipids and
macromolecules at 1.3p.p.m.þlactate, (3) N-acetyl aspartic acidþN-acetyl
aspartylglutamic acid, (4) glutamateþglutamine, (5) creatine, (6) choline
containing metabolites, (7) taurine, (8) glycineþmyo-inositol.
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smedulloblastomas. More recently, taurine was associated
with apoptotic activity in malignant adult brain tumours (Opstad
et al, 2009).
In this study, it was shown ex vivo by HR-MAS that PC is the
main contributor to the elevated CCM peak seen in vivo.A n
elevation of PC in medulloblastoma has also been confirmed in
several other studies using HR-MAS (Tugnoli et al, 2005; Wilson
et al, 2009b). A similar increase in PC has been shown to be related
to the expression of the MYCN oncogene in neuroblastoma, which
are histologically very similar to medulloblastoma (Peet et al,
2007b). The importance of choline metabolism has been related to
tumour growth in astrocytic tumours (Usenius et al, 1994) and in
numerous other studies reviewed by Podo (1999). This study is
also in agreement with the observation that glycine is elevated in
medulloblastoma (Wilson et al, 2009b) and supports recent
evidence that it may be a potential
1H MRS biomarker of
malignancy in childhood (Davies et al, 2010) and adult brain
tumours (Righi et al, 2010).
Lipid levels, as detected by
1H MRS, are not significantly high in
the SMO medulloblastomas, however, large variation in lipid levels of
orthotopic medulloblastomas in vivo has been reported (Rosol et al,
2009). It is commonly accepted that
1H MRS detected lipids are
localised in cytoplasmic lipid vesicles (Callies et al, 1993; Hakuma ¨ki
et al, 1998). Elevated
1H MRS lipid signals are associated with high
degree of malignancy in adult (Negendank and Sauter, 1996; Murphy
et al, 2003) and paediatric brain tumours (Astrakas et al, 2004; Albers
et al, 2005). MRS lipids are associated with cell death in tumours
either through apoptosis (Hakuma ¨ki and Kauppinen, 2000) or
necrosis (Kuesel et al, 1994). Recently, MRS lipids were linked to
tissue hypoxia in tumours (Zoula et al, 2003). Low levels of
1HM R S
detected lipids in the SMO medulloblastomas, which are highly
malignant with poor prognosis, are an unexpected observation in the
light of data from other high-grade brain tumours. These data
indicate that these medulloblastomas may be well perfused, without
significant hypoxia and cell death.
In conclusion, the genetically engineered SMO medulloblastoma
shares several MRI properties with human medulloblastomas.
Interestingly, we found that the metabolites pattern of the SMO
medulloblastoma resembles that of human medulloblastomas
which have already metastasised. This animal model is a suitable
tool for further experimental research including treatment studies.
This study suggests that
1H MRS will be of potential clinical value
primarily in differential diagnostic considerations.
Table 1 Metabolite concentrations (mM) determined from
1H MR spectra with the internal water as a reference
SMO mice SMO mice
Metabolite Wild type (n¼5) Normal T2 MRI (n¼8) T2 lesion (n¼10) t-Test ANOVA
Alanine 1.8±1.7 0.96±1.11 0.91±1.68 0.38 0.51
Aspartate 8.6±5.8 6.8±6.6 12.9±7.8 0.28 0.19
Creatine 10.6±2.5 8.3±2.1 8.5±2.3 0.16 0.16
g-Aminobutyric acid 2.5±4.0 6.6±4.8 7.3±7.0 0.14 0.30
Glycerophosphocholine 1.8±1.1 2.1±0.6 2.9±1.4 0.15 0.13
Glucose 5.9±3.6 3.9±2.1 3.8±2.8 0.31 0.35
Glutamine 11.4±10.9 9.3±6.4 9.7±7.4 0.77 0.89
Glutamate 10.6±9.3 10.1±5.8 6.1±3.7 0.35 0.31
Glycine 0.73±1.13 2.4±3.3 5.0±2.7 0.003 0.04
Guanidinoacetate 0.85±1.37 0.71±1.09 1.7±1.8 0.34 0.32
Myo-inositol 9.4±2.2 6.4±3.3 6.0±4.7 0.11 0.26
Lactate 3.4±1.8 1.3±1.3 3.6±4.0 0.90 0.16
N-acetylaspartate 2.0±2.5 2.3±1.9 0.35±0.77 0.22 0.07
N-acetylaspartylglutamate 4.4±2.9 2.7±2.1 1.0±0.6 0.06 0.02
Phosphocholine 0.38±0.66 0.33±0.51 1.2±1.4 0.16 0.12
Scyllo-inositol 0±0 0.09±0.22 0.46±0.67 0.09 0.11
Taurine 11.6±1.4 10.4±2.1 20.1±4.3 0.001 0.00
Lipid at 1.3p.p.m. 2.1±1.8 4.3±3.3 3.8±2.2 0.15 0.34
Macromolecule at 0.9p.p.m. 4.4±2.8 5.3±2.5 4.4±2.4 0.99 0.74
Total choline 2.2±0.6 2.4±0.5 4.2±1.0 0.0011 0.00
Total NAA 6.4±1.1 5.0±1.6 1.30±1.0 0.0000 0.00
Abbreviations: ANOVA¼analysis of variance; MR¼magnetic resonance; MRI¼magnetic resonance imaging; SMO¼smoothened. Values are means±standard deviations.
The Student’s t-test was performed between the wild-type and SMO mice with a T2 lesion, ANOVA was performed between the three groups.
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Figure 5 Example
1H HR-MAS spectra from (A) SMO mouse
cerebellum with a T2 MRI visible focal lesion and (B) a WT mouse
cerebellum. Peak assignments are as follows: (1) choline, (2) phosphocho-
line, (3) glycerophosphocholine, (4) taurine, (5) phosphatidylcholine,
(6) myo-inositol and (7) glycine.
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